Ariel Perez

Some days remind you why we do this. Our patients’ courage never ceases to inspire. Honored to give a survivor medal to a brave patient—2 years post-ASCT for MCL (image posted with permission) @BaptistHealthSF

Very productive @FLASCO_ORG Business of Oncology Summit yesterday. It was a pleasure to participate alongside such an outstanding faculty group. Don’t miss the education sessions at the Spring Congress—now underway.

@MarcoLDavila You sure don’t get that view in Buffalo😅

Ahhhhh… Miami

@HayderSaeed_MD @OncoDailyBio Congrats Hayder

Thank you @OncoDailyBio for the spotlight—really appreciate you highlighting this milestone. Grateful for the community pushing oncology forward. #OncoDaily #Oncology #Hematology #lymsm #CancerResearch #MedEd #ClinicalResearch #CancerCare #MedTwitter #HemeOnc

Registration is open for the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies 🗓️ Mar 6–7, 2026 bapth.lt/ImmunoSummit #HemeOnc #CART #AML #Lymphoma #MultipleMyeloma

Great MRD in AML session #Tandem26 Loved the practical insights from Dr Nadia Bambace and @SagheerTiba Lots of takeaways for real world practice. Privileged to work with them @BaptistHealthSF

@RahulBanerjeeMD @Bethfaiman @JCO_ASCO @jmikhaelmd @SLentzsch Congrats Rahul. Great article

8/ Link to @JCO_ASCO article: ascopubs.org/doi/suppl/10.1… Thanks again to all co-authors, esp #andrewcowan and @jmikhaelmd, for inspiration to take this on - and @SLentzsch for encouraging us to dream bigger with our #downwithdex vision. Would love all of your thoughts as well!

1/ Extremely appreciative of @JCO_ASCO @SLentzsch for opportunity to write about #downwithdex in myeloma #MMsm and AL amyloidosis. Quite a history going back >70 years to observations that ACTH infusions lowered M-spike 🤯 We've come a long way since then, but more to go! 🧵

Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. Co-authored by @DholariaMD. Read the full article. brnw.ch/21wYHmR

@Dr_AmerZeidan @ASH_hematology 2020 was my first ASH (virtual) and then in 2021 got my first in person poster photo (could not find the unmasked version)

Concluding another amazing #ASH2025 @ASH_hematology meeting. The picture is me attending my first ASH meeting with my first poster in San Francisco in 2008 and I have been to every single ASH meeting since then. When was your first ASH?

Phase 1b double-dose axi-cel presented by Caroline Lee (Stanford). High response rates with axi-cel 2, greater CAR AUC with less exhausted phenotypes and low added toxicity. Excellent talk!

Excited to be in Orlando for #ASH25. A special thanks to the organizers for the birthday gift. My collection of heme socks continues to grow!

CAR-T in PCNSL #lymsm - 67 pts, 25% CSF+, 12% eye+ - 57% axicel, 30% tisacel - 58% CR, 1-yr PFS 50%, 1-yr OS 66% - 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28% - 27% G3+ ICANS! Almost all got bridging; would love to know which agents. academic.oup.com/neuro-oncology…

An honor and a privilege to have been part of this collaborative study across frontline DLBCL trials.

But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs! v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500... Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!

I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇 onlinelibrary.wiley.com/share/author/4… 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes. 💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%). 💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity. ❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL 🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X. Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅 👉Please share with your network if you learnt something with this post 🙏 #HemOnc #MedEd #lymphomasm #CARTcelltherapy

I am thrilled to announce my promotion to Medical Director of Cellular Therapy. It has been an amazing 4 years since I joined @BaptistHealthSF. I am looking forward to continue developing the Miami Cancer Institute adoptive cell therapy program with our amazing team and leaders.

@BLLPHD Finally, awake after a long REMS slumber!!! @ASTCT astctjournal.org/article/S2666-…

Using CARTs for first relapse in myeloma. #mmsm open.substack.com/pub/rafaelfons…

@KRejeski @Eddie_Cliff @gloria_iacoboni @Kersten_MJ @AnnaSureda5 @i_yakoub_agha @MSubklewe Congrats Kai

Whirlwind day at #EHA25 presenting first on eligibility + longterm safety of CAR-T in 2L LBCL and then receiving this years EHA Publication Award for our ICAHT work in the Presidential Session 🙌 Grateful to share these moments with friends, collaborators and fantastic mentors!

Thank you to @MichaelDJain from @MoffittNews for helping us create this guide and sharing his insights on life after lymphoma. #lymsm